Empowering Cancer Decisions with OncoMetric Hub Insights

NeoVax Response Estimator

Predict the potential responsiveness of pancreatic tumors to personalized neoantigen-based mRNA vaccine therapies

Upload Genomic Sequencing Data

Please upload genomic sequencing data from tumor biopsies to analyze neoantigen profiles.

Drag and drop your files here or click to browse

Supported formats: VCF, FASTQ, BAM, or custom neoantigen prediction outputs

Sample Information

Patient ID (optional)

Tumor Type

Estimated Tumor Purity (%)

Immune Status Parameters

Tumor Mutation Burden (mutations/Mb)

MMR/MSI Status

Immune Checkpoint Expression

PD-L1 Expression > 1%

CTLA-4 Expression

LAG-3 Expression

Previous Treatment History

Prior Chemotherapy

Prior Radiation Therapy

Prior Immunotherapy

Prior Targeted Therapy

Advanced Parameters (Optional)

T-cell Infiltration Score (0-10)

HLA Type

Analyzing neoantigen profiles...

Neoantigen Vaccine Response Prediction

Summary

Neoantigen Profile

Treatment Recommendations

Response Prediction Summary

Key Factors Influencing Prediction

Predicted Neoantigens

Based on the genomic data analysis, the following neoantigens were identified and evaluated for potential immunogenicity:

Neoantigen	HLA Restriction	Binding Affinity	Immunogenicity Score

Recommended Vaccine Approach

Combination Strategy Recommendations

Monitoring Recommendations

Detailed Technical Information

The NeoVax Response Estimator uses a multi-parameter algorithm to analyze tumor genomic data and predict responsiveness to personalized neoantigen vaccines. The prediction model is based on:

Neoantigen burden and quality analysis
HLA binding affinity predictions
T-cell recognition probability
Tumor microenvironment assessment
Comparison against a curated database of known responders and non-responders

Scores are calculated using a weighted algorithm that prioritizes high-quality neoantigens with strong MHC binding and T-cell recognition potential.

The predictive model has been validated using retrospective analysis of clinical trial data from neoantigen vaccine studies. Validation metrics:

Sensitivity: 78%
Specificity: 82%
Positive Predictive Value: 75%
Negative Predictive Value: 84%

For detailed methodology and validation references, please contact our scientific support team.

While this tool provides valuable predictive guidance, it has several limitations:

Predictions are based on currently available data and may evolve as more clinical evidence emerges
Individual patient factors not captured in the genomic analysis may influence actual response
The tool is optimized for pancreatic tumors and may have reduced accuracy for other cancer types
Experimental validation is always recommended before clinical decision-making

NeoVax Response Estimator (Simulation)

Predict the potential responsiveness of pancreatic tumors to personalized neoantigen-based mRNA vaccine therapies based on simulated genomic characteristics. This tool is a conceptual simulation ONLY and is NOT intended for clinical or research use. Real neoantigen prediction is highly complex.

1. Tumor Genomic Data Input

Upload Tumor Genomic Sequencing Data (e.g., VCF, BAM):

Note: File content is NOT processed in this simulation. Select parameters below based on your data analysis.

2. Simulated Genomic & Neoantigen Characteristics

Select the options that best represent the findings from your genomic data analysis.

Estimated Neoantigen Load (NAL):

Tumor Mutational Burden (TMB) Category:

Presence of High-Quality Neoantigen Markers (Illustrative):

High Clonal Neoantigen Frequency Strong Predicted HLA Binding Affinity Associated Gene Expression High

Simplified HLA Compatibility Score:

Disclaimer & Important Notes

This calculator is a highly simplified simulation for educational and illustrative purposes only. It does NOT perform real genomic analysis or neoantigen prediction.

The scoring logic is hypothetical and not based on clinically validated algorithms. Neoantigen vaccine development and response prediction are complex research areas.

DO NOT use this tool for any clinical decision-making or patient care. Always rely on expert bioinformatics analysis, clinical trial data, and consultation with oncologists and researchers.